Cell therapy trial for active pemphigus vulgaris
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be confirmed to have pemphigus vulgaris (PV), usually by biopsy and positive DSG3 blood testing
- Your pemphigus must be active (not under full control) at the screening visit
- You must have tried at least one standard immunosuppressing medicine and it did not work well enough
- You must be at least 18 years old for the CABA-201 part of the study
- You should not be on high-dose prednisone (above 0.25 mg/kg/day)
- You likely cannot have had certain recent treatments (investigational drugs or anti-CD20/19 medicines like rituximab) unless specific exceptions apply
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
This trial compares two treatment combinations for moderate-to-severe pemphigus: rituximab plus steroids versus steroids plus azathioprine. The goal is to find which approach controls the disease better while reducing side effects.
This trial tests a new drug called CM313 for people with moderate to severe pemphigus, a blistering skin condition. It's for patients who haven't had this treatment before and may have not responded well to other therapies.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
Hear when a new Pemphigus Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.